

*Inter Partes Review of USPN 7,668,730
Par and Amneal Exhibit List*

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS, LLC and
PAR PHARMACEUTICAL, INC
Petitioners

v.

JAZZ PHARMACEUTICALS, INC.
Patent Owner

CASE IPR: Unassigned
Patent 7,668,730

**PAR PHARMACEUTICAL, INC., AND
AMNEAL PHARMACEUTICALS, LLC'S EXHIBIT LIST
(PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO.
7,668,730)**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

*Inter Partes Review of USPN 7,668,730
Par and Amneal Exhibit List*

Par Exhibit #	Description
1001	Reardan, <i>et al.</i> , U.S. Patent No. 7,668,730 (filed Dec. 17, 2002; issued Feb. 23, 2010)
1002	File History for U.S. Patent No. 7,668,730 (filed Dec. 17, 2002; issued Feb. 23, 2010)
1003	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Transcript and Slides (July 13, 2001)
1004	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information, Division of Neuropharmacological Drug Products Preliminary Clinical Safety Review of NDA 21-196 (July 13, 2001)
1005	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information, Briefing Booklet (July 13, 2001)
1006	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information, Xyrem Video and Transcript
1007	Declaration of Dr. Robert J. Valcuk, Ph.D., R.Ph.
1008	<i>Curriculum Vitae</i> of Dr. Robert J. Valuck, Ph.D., R.Ph.
1009	Shulman, S., "The Broader Message of Accutane," <i>Am. J. of Public Health</i> , 79:1565-1568 (1989)
1010	Spurgeon, D., "Advent of Mail-Order Pharmacy Causes Concern Among Some Pharmacists," <i>Can. Med. Assoc. J.</i> , 152:1485-1486 (1995)
1011	Honigfeld, G., "Effects of the Clozapine National Registry System on Incidence of Deaths Related to Agranulocytosis," <i>Psychiatric Services</i> , 47:52-56 (1996)
1012	Burleson, K., "Review of computer applications in institutional pharmacy—1975-1981," <i>Am. J. Hosp. Pharm.</i> , 39:53-70 (1982)
1013	Zeldis, J., <i>et al.</i> , "S.T.E.P.S. TM : A comprehensive Program for Controlling and Monitoring Access to Thalidomide," <i>Clin. Therapeutics</i> , 21:319-330 (1999)

*Inter Partes Review of USPN 7,668,730
Par and Amneal Exhibit List*

Par Exhibit #	Description
1014	“Managing the Risks from Medical Product Use: Creating a Risk Management Framework,” Report to the FDA Commissioner from the Task Force on Risk Management, U.S. Dept. of Health and Human Services, Food and Drug Administration (1999)
1015	66 Fed. Reg. 24391
1016	INTENTIONALLY LEFT BLANK
1017	FDA Center for Drug Evaluation and Research, 2001 FDA Advisory Committee’s Meeting Documents by Center, <i>available at</i> http://www.fda.gov/ohrms/dockets/ac/01docsbc.htm
1018	Internet Archive Wayback Machine, Center for Drug Evaluation and Research 2001 Meeting Documents, <i>available at</i> https://web.archive.org/web/20010617210030/http://www.fda.gov/ohrms/dockets/ac/cder01.htm (dated June 17, 2001)
1019	Internet Archive Wayback Machine, FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information for Xyrem NDA 21-196, <i>available at</i> https://web.archive.org/web/20010701233052/http://www.fda.gov/ohrms/dockets/ac/01/briefing/3754b1.htm (dated July 1, 2001)
1020	Internet Archive Wayback Machine, Center for Drug Evaluation and Research 2001 Meeting Documents, <i>available at</i> https://web.archive.org/web/20011004081740/http://www.fda.gov/ohrms/dockets/ac/cder01.htm (dated Oct. 4, 2001)
1021	Orange Book Entries for Xyrem®, <i>available at</i> http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=021196&TABLE1=OB_Rx ; and http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021196&Product_No=001&table1=OB_Rx
1022	Rome, E., “It’s a rave new world: Rave culture and illicit drug use in the young,” <i>Cleveland Clinic J. of Med.</i> , 68:541-550 (2001)

*Inter Partes Review of USPN 7,668,730
Par and Amneal Exhibit List*

Par Exhibit #	Description
1023	FDA Center for Drug Evaluation and Research, NDA 21-196, Approved Labeling, <i>available at</i> http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-196_Xyrem_prntlbl_P1.pdf
1024	INTENTIONALLY LEFT BLANK
1025	Complaint, <i>Jazz Pharms., Inc. v. Roxane Labs., Inc.</i> , 2:11-cv-02523 (D.N.J. May 5, 2011)
1026	Complaint, <i>Jazz Pharms., Inc. v. Par Pharm., Inc.</i> , 2:13-cv-07884 (D.N.J. Dec. 27, 2013)
1027	FDA's Center for Drug Evaluation and Research, Advisory Committees CDER 2001 Meeting Documents, <i>available at</i> http://www.fda.gov/ohrms/dockets/ac/cder01.htm#Peripheral%20&%20Central%20Nervous 1/
1028	Affidavit from the Internet Archive Wayback Machine
1029	Mitchell, A., "A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin," <i>The New England Journal of Medicine</i> , 333:101-106 (1995)
1030	Moradi <i>et al.</i> , U.S. Patent Appl. Pub. No. 2004/0019794 (filed Jul. 29, 2002; published Jan. 29, 2004)
1031	Lilly <i>et al.</i> , U.S. Patent Appl. Pub. No. 2003/0093295 (filed Jan. 31, 2002; published May 15, 2003)
1032	Scrima, L., <i>et al.</i> , "Efficacy of Gamma-Hydroxybutyrate versus Placebo in Treating Narcolepsy-Cataplexy: Double-Blind Subjective Measures," <i>Biol. Psychiatry</i> , 26:331-343 (1989).
1033	Talk About Sleep, "An Interview with Orphan Medical," <i>available at</i> http://www.talkaboutslee.com/an-interview-with-orphan-medical-about-xyrem/ (last visited Dec. 15, 2014) (Feb. 12, 2001)

*Inter Partes Review of USPN 7,668,730
Par and Amneal Exhibit List*

Par Exhibit #	Description
1034	Honigfeld, G., <i>et al.</i> , “Reducing Clozapine-Related Morbidity and Mortality: 5 Years of Experience with the Clozaril National Registry,” <i>Journal of Clinical Psychiatry</i> 59 (suppl. 3): 3-7 (1998)
1035	Elsayed <i>et al.</i> , U.S. Patent No. 6,045,501 (filed Aug. 28, 1998; issued Apr. 4, 2000)
1036	Lilly <i>et al.</i> , U.S. Patent Application No. 2004/0176985 A1 (filed Mar. 18, 2004 and claiming priority to U.S. Patent Application No. 10/062,251, filed Jan. 31, 2002; published Sep. 9, 2004) (“Lilly”)
1037	U.S. Provisional Patent Application Ser. No. 60/332,807 (“807 application) filed November 14, 2001.
1038	INTENTIONALLY LEFT BLANK
1039	January 13, 2014 Email from A. Burgy to G. Brier, re: Jazz v. Par, Civil Action No. 13-7884

Respectfully Submitted,



Aziz Burgy
Registration No. 51,514
Attorney for Petitioner

Date: January 8, 2015
ARENT FOX LLP
1717 K Street, NW
Washington, DC 20006
202.857.6000

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.